UCB’s general manager for Iberia, Pau Ricós, comments on the Belgian company’s upcoming launches, its focus on immunology and neurology, and the…

Merck Italia's Managing Director & President, Jan Kirsten explains the importance of the Italian affiliate within the global organisation, Merck's…

Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of…

Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights…

Newly-appointed general manager of UCB France, Catherine Rives, discusses what drew her back to the company after time away, market access issues in…

Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues,…

Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s…

Alessandro di Napoli, CEO of Swiss family-owned pharmaceutical group, TRB Chemedica, discusses the company’s focus on the rheumatology,…

In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has…

Appointed in the midst of the Greek economic crisis, compounded by significant changes at the corporate Merck brand, Merck Greece’s MD, Konstantinos…

Alberto Gugliemo, President of the Carlo Besta Institute in Milan, shares the changing perception of neurological diseases and neurological science in…

Pascal Brossard, the Managing Director of Zambon France and President of Afipa (Association for the French self-medication medicines industry),…